Show simple item record

dc.contributor.authorKarakuş, Volkan
dc.contributor.authorMaral, Senem
dc.contributor.authorKaya, Egemen
dc.contributor.authorGemici, Aliihsan
dc.contributor.authorDere, Yelda
dc.contributor.authorSevindik, Ömür Gökmen
dc.date.accessioned2022-10-31T09:36:16Z
dc.date.available2022-10-31T09:36:16Z
dc.date.issued2022en_US
dc.identifier.citationKarakuş, V., Maral, S., Kaya, E., Gemici, A., Dere, Y. ve Sevindik, Ö. G. (2022). Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data. Northern Clinics of Istanbul, 9(4), 331-336. https://doi.org/10.14744/nci.2021.42800en_US
dc.identifier.issn2148-4902
dc.identifier.issn2536-4553
dc.identifier.urihttps://doi.org/10.14744/nci.2021.42800
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9897
dc.description.abstractOBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of life have improved. However, long-term management in elderly and frail patients is still a challenge. In the present study, we aimed to determine whether HMA maintenance therapy is required until disease progression in frail and elderly AML patients by examining with a real-life data.METHODS: In a multicenter study, we analyzed non-promyelocytic elderly AML patients who were treated with first-line azacitidine or decitabine monotherapy in two different groups, retrospectively. While patients were treated with HMA until progression in the maintenance group, 6+3 cycles of azacitidine or decitabine were administered as a standard care of elderly AML patients in the non-maintenance group. Survival outcomes were compared between the groups.RESULTS: HMA therapy was maintained until progression in 20 patients, and HMA therapy was terminated after 6+3 cycles in 21 patients. Patients received a median of 6 (1-14) HMA cycles during follow-up time. The median 7.5 months of overall survival were observed (2-17 months) in maintenance and 3 months (1-13 months) in non-maintenance groups (p=0.001).CONCLUSION: Despite long-term exposure to HMA may appear as a risk factor for complications and toxicities in elderly and frail AML patients, the maintenance of therapy until disease progression provides a significant survival advantage. Therefore, we suggest that HMA therapy should continue until disease progression regardless the sort of HMA.en_US
dc.language.isoengen_US
dc.publisherKare Publishingen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectAzacitidineen_US
dc.subjectDecitabineen_US
dc.subjectHypomethylating Agentsen_US
dc.titleSurvival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience dataen_US
dc.typearticleen_US
dc.relation.ispartofNorthern Clinics of Istanbulen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-3385-8359en_US
dc.authorid0000-0001-9636-4113en_US
dc.identifier.volume9en_US
dc.identifier.issue4en_US
dc.identifier.startpage331en_US
dc.identifier.endpage336en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.14744/nci.2021.42800en_US
dc.institutionauthorGemici, Aliihsan
dc.institutionauthorSevindik, Ömür Gökmen
dc.identifier.wos000864526600007en_US
dc.identifier.scopus2-s2.0-85164768023en_US
dc.identifier.trdizinid1130076en_US
dc.identifier.pmid36276561en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record